MX2016015565A - Ciertos inhibidores de la proteina quinasa. - Google Patents

Ciertos inhibidores de la proteina quinasa.

Info

Publication number
MX2016015565A
MX2016015565A MX2016015565A MX2016015565A MX2016015565A MX 2016015565 A MX2016015565 A MX 2016015565A MX 2016015565 A MX2016015565 A MX 2016015565A MX 2016015565 A MX2016015565 A MX 2016015565A MX 2016015565 A MX2016015565 A MX 2016015565A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitors
certain protein
certain
inhibitors
Prior art date
Application number
MX2016015565A
Other languages
English (en)
Inventor
Weibo Wang
Weipeng Zhang
Li Tongshuang
Zhao Xingdong
Tian Qiang
Zhang Huajie
Tan Haohan
Wang Xianlong
Liu Qihong
Li Zhifu
Jiang Lihua
Liu Yanxin
Lin Min
Sun Jing
Chen Zhifang
LINGHU Li
Original Assignee
Shanghai Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fochon Pharmaceutical Co Ltd filed Critical Shanghai Fochon Pharmaceutical Co Ltd
Publication of MX2016015565A publication Critical patent/MX2016015565A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan compuestos de fórmula (I) como ciertos inhibidores de la CDK4/6, composiciones farmacéuticas de los mismos, y métodos para usarlos.
MX2016015565A 2014-05-28 2015-05-27 Ciertos inhibidores de la proteina quinasa. MX2016015565A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003626P 2014-05-28 2014-05-28
PCT/CN2015/079910 WO2015180642A1 (en) 2014-05-28 2015-05-27 Certain protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2016015565A true MX2016015565A (es) 2017-07-04

Family

ID=54698110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015565A MX2016015565A (es) 2014-05-28 2015-05-27 Ciertos inhibidores de la proteina quinasa.

Country Status (13)

Country Link
US (1) US10087195B2 (es)
EP (1) EP3149008B8 (es)
JP (1) JP2017516855A (es)
KR (1) KR101864589B1 (es)
CN (2) CN106795179B (es)
AU (1) AU2015266492B2 (es)
BR (1) BR112016027679B1 (es)
CA (1) CA2950330C (es)
DK (1) DK3149008T3 (es)
ES (1) ES2715462T3 (es)
MX (1) MX2016015565A (es)
RU (1) RU2671494C2 (es)
WO (1) WO2015180642A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106188060A (zh) 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
WO2017114351A1 (en) * 2015-12-27 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
ES2954148T3 (es) * 2016-05-07 2023-11-20 Fochon Pharmaceuticals Ltd Ciertos inhibidores de proteína cinasa
WO2018005860A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
CN113264935B (zh) 2016-11-11 2022-09-20 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物及其中间体和医药上的用途
CN107312006B (zh) * 2017-06-28 2019-11-15 郑州大学第一附属医院 吡咯并嘧啶类衍生物及其应用
MX2020006587A (es) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
WO2019206154A1 (zh) 2018-04-24 2019-10-31 上海海雁医药科技有限公司 Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
CN112094272A (zh) * 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
IL298294A (en) 2020-05-19 2023-01-01 G1 Therapeutics Inc Cyclin-dependent kinase inhibitory compounds for the treatment of medical disorders
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY134589A (en) * 2002-09-23 2007-12-31 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors
US7405220B2 (en) * 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
SI2215094T1 (sl) * 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
EP2331547B1 (en) * 2008-08-22 2014-07-30 Novartis AG Pyrrolopyrimidine compounds as cdk inhibitors
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20120115878A1 (en) * 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
FR2988722B1 (fr) * 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques

Also Published As

Publication number Publication date
CA2950330A1 (en) 2015-12-03
ES2715462T3 (es) 2019-06-04
RU2016151315A3 (es) 2018-07-02
US20170267696A1 (en) 2017-09-21
EP3149008B8 (en) 2019-03-06
EP3149008B1 (en) 2018-12-12
KR20170023872A (ko) 2017-03-06
KR101864589B1 (ko) 2018-07-04
CN110372720B (zh) 2021-03-05
BR112016027679B1 (pt) 2022-10-25
US10087195B2 (en) 2018-10-02
CN106795179B (zh) 2019-09-17
CN110372720A (zh) 2019-10-25
AU2015266492A1 (en) 2017-01-19
WO2015180642A1 (en) 2015-12-03
DK3149008T3 (en) 2019-04-01
EP3149008A4 (en) 2018-01-17
AU2015266492B2 (en) 2017-11-02
CA2950330C (en) 2019-04-30
CN106795179A (zh) 2017-05-31
BR112016027679A2 (es) 2017-08-15
JP2017516855A (ja) 2017-06-22
RU2016151315A (ru) 2018-07-02
EP3149008A1 (en) 2017-04-05
RU2671494C2 (ru) 2018-11-01

Similar Documents

Publication Publication Date Title
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
TW201613911A (en) Heterocyclic compounds and uses thereof
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201591420A1 (ru) Гетероарильные соединения и их применение
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
TW201613864A (en) Novel compounds
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof